mRNA-4359

mRNA-4359 is an investigational mRNA-based cancer vaccine developed by Moderna for the treatment of advanced solid tumors. It encodes instructions for the production of two proteins—indoleamine 2,3-dioxygenase (IDO1) and programmed cell death ligand 1 (PD-L1)—which are involved in immune regulation and tumor immune evasion. Delivered via lipid nanoparticles, mRNA-4359 aims to stimulate the immune system to recognize and attack cancer cells expressing these targets. The drug is being evaluated both as a monotherapy and in combination with pembrolizumab (an anti-PD-1 antibody) in Phase 1/2 clinical trials for various advanced solid tumors, including melanoma, non-small cell lung carcinoma, bladder cancer, head and neck squamous cell carcinoma, microsatellite stable colorectal cancer, basal cell carcinoma, and triple negative breast cancer[1][3][5][7].

Other names

mrna-derived ido/pd-l1-targeted vaccine